These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Kim J; Lee KH; Yoo S; Pai H Int J Antimicrob Agents; 2009 Nov; 34(5):434-8. PubMed ID: 19726164 [TBL] [Abstract][Full Text] [Related]
35. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452 [TBL] [Abstract][Full Text] [Related]
37. [Research progress in mechanisms of drug-induced nephrotoxicity]. Mao HX Zhongguo Dang Dai Er Ke Za Zhi; 2014 Apr; 16(4):330-4. PubMed ID: 24750824 [TBL] [Abstract][Full Text] [Related]
40. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M; Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]